Tao Yang

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Venues

Emerging microbes & infections

This page only lists publications with an associated author ORCID identifier.

Publications

Tao Yang, Zhiman Xie, Zhe Xu, Bo Tu, Huan Lu, Huihuang Huang, Lei Huang, Chao Zhang, Liying Gao, Lei Jin, Ping Ma, Jun Zou, Limin Liu, Cheng Zhen, Chunbao Zhou, Sirun Meng, Yuan-Yuan Li, Jin-Wen Song, Shixiong Yang, Hui-Sheng Ai, Yan-Mei Jiao, Ming Shi, Ruonan Xu, Fu-Sheng Wang
HLA-mismatched allogeneic adoptive immune therapy in patients with severely immunosuppressed AIDS: a multicenter, open-label, controlled, phase 2a study. Emerging microbes & infections 13 (1) (2024)
Tao Yang, Zhiman Xie, Zhe Xu, Bo Tu, Huan Lu, Huihuang Huang, Lei Huang, Chao Zhang, Liying Gao, Lei Jin, Ping Ma, Jun Zou, Limin Liu, Cheng Zhen, Chunbao Zhou, Sirun Meng, Yuan-Yuan Li, Jin-Wen Song, Shixiong Yang, Hui-Sheng Ai, Yan-Mei Jiao, Ming Shi, Ruonan Xu, Fu-Sheng Wang
HLA-mismatched allogeneic adoptive immune therapy in patients with severely immunosuppressed AIDS: a multicenter, open-label, controlled, phase 2a study. Emerging microbes & infections 13 (1) (2024)
Tao Yang, Zhiman Xie, Zhe Xu, Bo Tu, Huan Lu, Huihuang Huang, Lei Huang, Chao Zhang, Liying Gao, Lei Jin, Ping Ma, Jun Zou, Limin Liu, Cheng Zhen, Chunbao Zhou, Sirun Meng, Yuan-Yuan Li, Jin-Wen Song, Shixiong Yang, Hui-Sheng Ai, Yan-Mei Jiao, Ming Shi, Ruonan Xu, Fu-Sheng Wang
HLA-mismatched allogeneic adoptive immune therapy in patients with severely immunosuppressed AIDS: a multicenter, open-label, controlled, phase 2a study. Emerging microbes & infections 13 (1) (2024)
Tao Yang, Zhiman Xie, Zhe Xu, Bo Tu, Huan Lu, Huihuang Huang, Lei Huang, Chao Zhang, Liying Gao, Lei Jin, Ping Ma, Jun Zou, Limin Liu, Cheng Zhen, Chunbao Zhou, Sirun Meng, Yuan-Yuan Li, Jin-Wen Song, Shixiong Yang, Hui-Sheng Ai, Yan-Mei Jiao, Ming Shi, Ruonan Xu, Fu-Sheng Wang
HLA-mismatched allogeneic adoptive immune therapy in patients with severely immunosuppressed AIDS: a multicenter, open-label, controlled, phase 2a study. Emerging microbes & infections 13 (1) (2024)

Tao Yang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Tao Yang